Skip to content

Allium Sativum Oil as Alternative Non-vital Pulpotomy Medicament in Primary Teeth

Allium Sativum Oil as Alternative Non-vital Pulpotomy Medicament in Primary Teeth- A Randomized Controlled Trial

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05801367
Enrollment
40
Registered
2023-04-06
Start date
2022-10-20
Completion date
2023-03-02
Last updated
2023-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Vital Tooth

Brief summary

The purpose of this randomized controlled clinical trial is to use Allium sativum oil as non-vital Pulpotomy medicament compared to Formocresol in primary teeth by evaluating its antibacterial effect against Streptococcus mutans and Lactobacillus acidophilus. It is hypothesized that there is no difference in the antibacterial effect of Allium sativum oil compared with Formocresol, when used as non-vital Pulpotomy medicaments.

Detailed description

It is a multi-arm parallel Randomized Controlled Trial in which forty patients aged between 4 to 8 years, each containing at-least one non-vital primary molar, will be selected and randomly divided into Group A (Formocresol) and Group B (Allium sativum oil). Non-vital Pulpotomy will be performed by removing the coronal necrotic pulp. Sterile paper point will be dipped in the root canals and taken to the laboratory. Cotton pellets soaked in the respective medicaments will be placed over the root canal orifices and filled temporarily. Patients will be recalled after one week. Samples will be again taken, and tooth restored. Comparison between bacterial count at baseline and after one week of treatment will be made and expressed as Colony-Forming Units/ml (CFU/ml).

Interventions

Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)

Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)

Sponsors

Lahore General Hospital
CollaboratorOTHER_GOV
University of Health Sciences Lahore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

patients and assessors involved in the study from randomization, allocation, bacteriological outcome, and data analysis will be blinded to which medicament group the patients belonged as all data will be coded.

Eligibility

Sex/Gender
ALL
Age
4 Years to 8 Years
Healthy volunteers
Yes

Inclusion criteria

1. Cooperation of patients and consent of parents. 2. Patients with ASA classification I and II (mild to moderate systemic disease). 3. Non-traumatic extensively carious hence restorable primary molars. 4. No history of antibiotic use for 2 weeks. 5. Presence of following clinical signs or symptoms suggestive of non-vital tooth such as tenderness on percussion, non-responsive to cold test, periapical/furcal radiolucency, localized gingival/mucosal soreness/redness/swelling, and/or slight mobility-grade I.

Exclusion criteria

1. History of allergy to anesthetics and latex. 2. Radiographic evidence of pulpal floor opening into the furcation area. 3. More than half of the roots resorbed.

Design outcomes

Primary

MeasureTime frameDescription
Antibacterial effect1 weekBacterial count of S. mutans and L. acidophilus counted as Colony Forming Units/ml (CFU/ml)

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026